In this study, researchers aimed to investigate whether discontinuing premedications after 2 doses of paclitaxel is safe and feasible in some breast cancer patients.

Four years after the FDA said there could be a higher risk of death with paclitaxel-coated devices used for peripheral arterial disease, the agency concluded July 11 the evidence does not support this ...

Sociodemographic Inequities in Telemedicine Use Among US Patients Initiating Treatment in Community Cancer Centers During the Ongoing COVID-19 Pandemic, 2020-2022 Infusion-related hypersensitivity ...

Please provide your email address to receive an email when new articles are posted on . Paclitaxel plus fluorouracil did not demonstrate OS superiority over paclitaxel plus cisplatin or paclitaxel ...

After more than four years of scientific review, the FDA is rolling back warnings over cardiovascular devices and implants coated with the drug paclitaxel, saying studies have shown they do not carry ...

Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...